TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 21, 2024 at 04:16 pm
Share
TELA Bio, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 17 million compared to USD 11.62 million a year ago. Net loss was USD 12.89 million compared to USD 9.98 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.52 a year ago.
For the full year, sales was USD 58.45 million compared to USD 41.42 million a year ago. Net loss was USD 46.66 million compared to USD 44.3 million a year ago. Basic loss per share from continuing operations was USD 2.04 compared to USD 2.72 a year ago.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
